Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-11-21

FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved Teva's supplemental application for a generic fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate for the trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (Efavirenz; Emtricitabine; Tenofovir disoproxil fumarate)

Snippet

SUPPL AP for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)